ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.14B |
| Gross Profit (TTM) | $706.66M |
| EBITDA | $98.39M |
| Operating Margin | 12.30% |
| Return on Equity | 35.70% |
| Return on Assets | 3.64% |
| Revenue/Share (TTM) | $6.69 |
| Book Value | $7.59 |
| Price-to-Book | 3.72 |
| Price-to-Sales (TTM) | 4.39 |
| EV/Revenue | 3.498 |
| EV/EBITDA | 40.48 |
| Quarterly Earnings Growth (YoY) | 13.30% |
| Quarterly Revenue Growth (YoY) | 16.40% |
| Shares Outstanding | $171.24M |
| Float | $128.35M |
| % Insiders | 0.33% |
| % Institutions | 99.80% |
Volatility is currently expanding
ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.
Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another q.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two stocks presents investors with the better value opportunity right now?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
The mean of analysts' price targets for Acadia (ACAD) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACAD and any ticker you trade — then tracks every position and per-strategy win rate.
